title: Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue.
abstract: Proteolytic enzyme inhibitors were examined as absorption enhancers for the nasal delivery of vasopressin (AVP) and desmopressin (1-d-8-DAVP) in rats. Aprotinin, soybean trypsin inhibitor, and camostat mesilate were used as enzyme inhibitors. The nasal absorption of AVP and 1-d-8-DAVP was evaluated by measuring its antidiuretic effect. Nasal administration of AVP (0.005 IU/kg) or 1-d-8-DAVP alone (2.5 ng/kg) produced a small antidiuretic effect. Coadministration with aprotinin (1000 and 10000 KIU/kg) or soybean trypsin inhibitor (1.25 and 6.25 mM) did not change the antidiuretic effect. However, coadministration with camostat mesilate (1 to 50 mM) significantly increased the antidiuretic effect and, thus, the nasal absorption of AVP and 1-d-8-DAVP. The activities of aminopeptidase, cathepsin-B, and trypsin in the nasal mucosal tissue of rats were 7 nmol/min/mg protein, 0.7 nmol/min/mg protein, and 4.6 pmol/min/mg protein, respectively. Aprotinin and soybean trypsin inhibitor inhibited only the trypsin activity, whereas camostat mesilate inhibited aminopeptidase and trypsin activities. Aprotinin (MW 6500) and soybean trypsin inhibitor (MW 8000), with relatively high molecular weights, may not permeate into the nasal mucosal tissue. In contrast, camostat mesilate is slowly absorbed (8%/hr) and could inhibit the proteolytic activity in the nasal mucosa, resulting in enhanced nasal absorption of AVP and 1-d-8-DAVP.
authors.affiliation: Department of Pharmaceutical Sciences, Osaka University of Pharmaceutical Sciences, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Morimoto
authors.forename: H
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Iwakura
authors.forename: M
authors.initials: M
authors.lastname: Miyazaki
authors.forename: E
authors.initials: E
authors.lastname: Nakatani
authors.forename: T
authors.initials: T
authors.lastname: Iwamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Y
authors.initials: Y
authors.lastname: Nakai
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D007611:Aprotinin / Q000494:pharmacology*; D001682:Biological Availability; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000378:metabolism; D004285:Dogs; D004952:Esters; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000494:pharmacology*; D008297:Male; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D014360:Trypsin Inhibitor, Kunitz Soybean / Q000494:pharmacology*; D014667:Vasopressins / Q000008:administration & dosage / Q000378:metabolism*
chemical_list: D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; C034532:camostat; D014667:Vasopressins; D016670:Gabexate; D007611:Aprotinin; D014360:Trypsin Inhibitor, Kunitz Soybean; D003894:Deamino Arginine Vasopressin